INAB

IN8bio, Inc. NASDAQ Listed Jul 30, 2021

Healthcare ·Biotechnology ·US · in8bio.com

$1.60

Mkt Cap $7.4M

52w Low $1.17 9.7% of range 52w High $5.61

50d MA $1.60 200d MA $1.93

P/E (TTM) -0.3x

EV/EBITDA 0.8x

P/B 0.2x

Debt/Equity 0.1x

ROE -70.5%

P/FCF -0.8x

RSI (14) —

ATR (14) —

Beta 0.04

50d MA $1.60

200d MA $1.93

Avg Volume 58.9K

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

CIK (SEC)

1740279

Phone

646 600 6438

350 5th Avenue · New York City, NY 10118 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-0.18	-0.26	-44.4%	1.91	-0.5%	-1.0%	+9.0%	-7.3%	-3.7%	-6.5%	—
Nov 6, 2025	AMC	-1.20	-0.85	+29.2%	1.66	-3.6%	-6.6%	+11.0%	-2.3%	+1.2%	-3.5%	—
Aug 7, 2025	AMC	-1.50	-1.24	+17.3%	2.15	+0.0%	+7.4%	-1.7%	-0.9%	+1.8%	+4.8%	—
May 7, 2025	AMC	-1.80	-2.10	-16.7%	4.93	+2.2%	+2.2%	-6.3%	+3.6%	-1.8%	-8.3%	—
Mar 13, 2025	AMC	-0.07	-0.04	+42.9%	6.79	+1.6%	-0.4%	+0.4%	+1.0%	+3.2%	-1.3%	—
Nov 12, 2024	AMC	-0.14	-0.15	-7.1%	10.50	-14.0%	-9.5%	+6.1%	-0.2%	-1.1%	-4.4%	—
Aug 8, 2024	AMC	-0.16	-0.19	-18.8%	20.52	+2.3%	+2.2%	-9.2%	+2.2%	-7.5%	+0.5%	—
May 9, 2024	AMC	-0.17	-0.20	-17.6%	30.30	-1.7%	+0.0%	+1.0%	+2.0%	+8.7%	-9.7%	—
Mar 14, 2024	AMC	-0.16	-0.21	-31.2%	34.80	+1.7%	-1.7%	+7.9%	-2.4%	+6.7%	-2.3%	—
Nov 9, 2023	AMC	-0.25	-0.23	+8.0%	30.30	-0.1%	+3.0%	+1.0%	-5.7%	-5.1%	-2.0%	—
Aug 10, 2023	AMC	-0.28	-0.27	+3.6%	34.50	+2.6%	+1.7%	+0.0%	+1.7%	-0.8%	-3.4%	—
May 12, 2023	AMC	-0.33	-0.30	+9.1%	70.50	-0.4%	+4.7%	+8.5%	+4.1%	+13.3%	+2.9%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.91	$1.90	-0.5%	-1.0%	+9.0%	-7.3%	-3.7%	-6.5%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.79	$6.90	+1.6%	-0.4%	+0.4%	+1.0%	+3.2%	-1.3%
Feb 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.20	$8.43	-8.4%	-5.1%	+11.0%	-10.0%	-8.1%	+10.2%
Feb 11	Jones Trading	Upgrade	Hold → Buy	—	$8.10	$11.96	+47.7%	+13.6%	-5.1%	+11.0%	-10.0%	-8.1%
Nov 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.11	$9.45	+3.7%	+2.1%	-4.4%	+2.8%	+20.8%	-13.2%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.50	$9.03	-14.0%	-9.5%	+6.1%	-0.2%	-1.1%	-4.4%
Aug 12	Jones Trading	Downgrade	Buy → Hold	—	$20.97	$20.70	-1.3%	-9.2%	+2.2%	-7.6%	+0.5%	+16.1%
Jun 14	Jones Trading	Maintains	Buy → Buy	—	$50.40	$45.00	-10.7%	-35.1%	-8.3%	+0.0%	-8.0%	-3.4%
Jun 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$50.40	$45.00	-10.7%	-35.1%	-8.3%	+0.0%	-8.0%	-3.4%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.70	$32.40	-0.9%	+12.8%	+11.4%	-17.5%	+18.6%	-2.2%
May 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$30.30	$30.90	+2.0%	+1.0%	+2.0%	+8.7%	-9.7%	+1.0%
Apr 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.70	$34.80	+6.4%	+0.9%	+4.5%	-3.5%	-8.1%	-3.9%
Mar 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$34.80	$35.40	+1.7%	-1.7%	+7.9%	-2.4%	+6.7%	-2.3%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$31.20	$32.10	+2.9%	+1.0%	-5.7%	-5.1%	-2.0%	-1.2%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$34.50	$35.40	+2.6%	+1.7%	+0.0%	+1.7%	-0.8%	-3.4%
Jun 5	EF Hutton	Maintains	Buy → Buy	—	$94.50	$91.50	-3.2%	-13.3%	-7.3%	+1.2%	-5.9%	-11.6%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$73.80	$73.80	+0.0%	+8.5%	+4.1%	+13.3%	+2.9%	-16.0%
Apr 17	EF Hutton	Maintains	Buy → Buy	—	$36.30	$38.40	+5.8%	+6.6%	-1.6%	-9.4%	-2.6%	-6.2%
Nov 11	B. Riley Securities	Downgrade	Buy → Neutral	—	$49.50	$52.50	+6.1%	+3.6%	-12.3%	+5.3%	-3.2%	-2.0%
Jan 24	B. Riley Securities	Maintains	Buy → Buy	—	$96.30	$92.40	-4.0%	+2.8%	+0.0%	-3.3%	-4.1%	-2.0%

Data updated apr 25, 2026 3:26pm · Source: massive.com